BESVIL G 100 Octacaps 30's

Introduction About BESVIL G 100 OCTACAPS

Besvil G 100 Octacaps is a triple-combination inhalation therapy containing fluticasone furoate, glycopyrronium, and vilanterol. It is commonly prescribed for adults with chronic obstructive pulmonary disease (COPD) and, in selected cases, asthma requiring long-term maintenance therapy. The combination works by helping keep the airways open while reducing airway inflammation, supporting better day-to-day breathing control and lung function.

This medicine is generally suitable for adults who experience persistent breathing difficulties, chronic cough, wheezing, chest tightness, or frequent COPD symptom flare-ups despite regular respiratory management. The inhaled corticosteroid component helps reduce airway inflammation, while the bronchodilator components support prolonged airway relaxation for up to 24 hours. Regular use may help improve symptom control, exercise tolerance, and overall respiratory comfort.

Besvil G 100 Octacaps is intended for inhalation only and should never be swallowed. The capsule is placed into the prescribed inhalation device (such as a octahaler), pierced according to device instructions, and the powder inhaled deeply through the mouth. After inhalation, patients should rinse their mouth with water and spit it out to maintain good oral hygiene. The medicine should be used consistently at the same time each day for optimal benefit. It is not designed for sudden breathing attacks, and patients should continue carrying any rescue inhaler prescribed by their healthcare professional.

Before starting therapy, patients should inform their healthcare professional about any history of glaucoma, cataracts, heart disease, high blood pressure, diabetes, thyroid disorders, urinary retention, enlarged prostate, liver disease, kidney disease, osteoporosis, or recurrent infections. Use during pregnancy or breastfeeding should only occur when a healthcare professional determines that the expected benefits outweigh potential risks.

Commonly reported side effects include headache, cough, sore throat, hoarseness, runny or blocked nose, fever, joint pain, back pain, stomach discomfort, and increased blood pressure. Most effects are mild and temporary, but persistent symptoms should be discussed with a healthcare professional. Besvil G 100 Octacaps is generally not recommended for children and adolescents below 18 years of age.

Uses Of BESVIL G 100 OCTACAPS

• Besvil -G 100 is indicated for the maintenance of patients with moderate to severe COPD.

Benefits of BESVIL G 100 OCTACAPS

• Helps keep the airways open, making breathing easier.
• Supports better airflow to and from the lungs.
• Helps reduce breathlessness during daily activities.
• Assists in controlling airway inflammation.
• Supports long-term management of chronic respiratory conditions.
• Helps reduce wheezing, chest tightness, and breathing discomfort.
• Provides triple-action respiratory support through three complementary medicines.
• Offers once-daily convenience for easier management adherence.
• Helps maintain lung function with regular use.
• Supports improved day-to-day respiratory comfort and quality of life.

How BESVIL G 100 OCTACAPS Works

• Fluticasone furoate and vilanterol represent two classes of medications (a synthetic corticosteroid and a selective, long-acting beta-receptor 2 agonist).
• Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator management of COPD.
• Parasympathetic nerves are the major bronchoconstrictive neural pathway in airways, and cholinergic tone is the key reversible component  of airflow obstruction in COPD.
• Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways. Glycopyrronium bromide is a high affinity muscarinic receptor antagonist.  A greater than 4-fold selectivity for the human M3 receptors over the  human M2 receptor has been demonstrated using radioligand binding studies.
• It has a rapid onset of action as evidenced by observed receptor association/dissociation kinetic parameters and the onset of action after inhalation in clinical studies.
• The long duration of action can be partly attributed to sustained concentrations of active substance in the lung as reflected by the  prolonged terminal elimination half-life of glycopyrronium after inhalation via the Besvil -G 100 inhaler in contrast to the half-life after intravenous administration.

How to use BESVIL G 100 OCTACAPS

Patients should not stop therapy in COPD without physician supervision since symptoms may recur after discontinuation.

Before Using the Octacap

• Read the instructions provided with the inhalation device carefully.
• Ensure the inhalation device is clean and dry.
• Wash and dry your hands before handling the capsule.
• Remove only one capsule from the blister immediately before use.

Important Administration Instructions

• Besvil G Octacaps are for inhalation only.
• Do not swallow the capsule.
• Besvil -G 100 capsules are intended for use through Octahaler only
• Do not place the capsule directly into the mouth.

Step-by-Step Inhalation Process

Step 1: Prepare the Device

• Open the inhalation device according to the manufacturer's instructions.
• Place one capsule into the capsule chamber.

Step 2: Pierce the Capsule

• Close the device properly.
• Press the piercing buttons as instructed to puncture the capsule.
• Do not pierce the capsule more than once unless directed by the device instructions.

Step 3: Exhale Fully

• Breathe out gently away from the device.
• Never exhale into the mouthpiece.

Step 4: Inhale the Medicine

• Place the mouthpiece between your lips.
• Take a deep, forceful, and steady breath through the mouth.
• You may hear a vibrating sound as the capsule spins inside the device.

Step 5: Hold Your Breath

• Remove the inhaler from your mouth.
• Hold your breath for approximately 5–10 seconds or as long as comfortable.
• Breathe out slowly.

Step 6: Check the Capsule

• Open the device and inspect the capsule.
• If powder remains, repeat inhalation once more to ensure complete delivery.

Step 7: Dispose of the Empty Capsule

• Remove and discard the used capsule.
• Do not reuse capsules.

After Each Dose

Rinse Your Mouth

• Rinse your mouth thoroughly with water.
• Spit out the water; do not swallow.
• This helps maintain oral hygiene after inhalation therapy.

Clean the Device

• Follow the manufacturer's cleaning instructions.
• Keep the inhalation device dry.
• Store the device in a clean location.

When to Use Besvil G 100 Octacaps

• Use exactly as prescribed by your healthcare professional.
• Usually administered once daily.
• Take it at the same time every day to maintain consistent respiratory support.
• Continue using it regularly even when feeling well unless advised otherwise by your healthcare professional.

Patient Tips for Best Results

• Use the inhalation technique correctly every time.
• Keep track of your dosing schedule.
• Attend regular follow-up appointments to assess lung function and inhaler technique.
• Carry any separately prescribed rescue inhaler for sudden breathing difficulties, as Besvil G is intended for regular maintenance therapy.

What if I forgot to take BESVIL G 100 OCTACAPS

• If a dose is missed, take it as soon as remembered on the same day.
• If it is almost time for the next dose, skip the missed dose.
• Do not take extra doses to make up for a missed dose.

Overdose

Fluticasone Furoate and Vilanterol

• Symptoms and signs: An overdose of fluticasone furoate/vilanterol may produce signs and symptoms due to the individual component's actions, including those seen with overdose of other beta-agonists and consistent 2 with the known inhaled corticosteroid class effects.
• Acute intoxication by inadvertent oral ingestion of fluticasone and vilanterol, capsules is unlikely due to the low oral bioavailability (about 5%).
• There is no specific management for an overdose with fluticasone furoate/vilanterol. If overdose occurs, the patient should be managed supportively with appropriate monitoring as necessary.
• Cardioselective beta-blockade should only be considered for profound vilanterol overdose effects that are clinically concerning and unresponsive to supportive measures.
• Cardioselective beta-blocking medicinal products should be used with caution in patients with a history of  bronchospasm. Further management should be as clinically indicated.

Glycopyrronium

• High doses of glycopyrronium may lead to anticholinergic signs and symptoms for which symptomatic management may be indicated.
• Acute intoxication by inadvertent oral ingestion of glycopyrronium, capsules is unlikely due to the low oral bioavailability (about 5%).
• Peak plasma levels and total systemic exposure following intravenous administration of 150 micrograms glycopyrronium bromide (equivalent to 120 micrograms glycopyrronium) in healthy volunteers were respectively about 50-fold and 6-fold higher than the peak and total exposure at steady state achieved with the recommended dose (44 micrograms once daily)
  of glycopyrronium and were well tolerated.

Systemic corticosteroid effects
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).

Side Effects Of BESVIL G 100 OCTACAPS

Common

• Headache
• Nasopharyngitis
• Pneumonia
• Fractures

When to consult a doctor?

• Asthma-related adverse events and exacerbations
• If asthma symptoms remain uncontrolled or worsen after initiation of Besvil -G 100.
• Paradoxical bronchospasm with an immediate increase in wheezing after dosing.
• Blurred vision or other visual disturbances,

Warning & Precautions

Other Warnings for BESVIL G 100 OCTACAPS

Inform your healthcare professional about any history of

• Glaucoma
• Cataracts
• Diabetes
• Thyroid disorders
• Osteoporosis
• Recurrent infections

Drug - Drug interaction

Strong CYP3A4 Inhibitors

These medicines may increase the levels of fluticasone or vilanterol in the body:

• Ketoconazole
• Itraconazole
• Voriconazole
• Clarithromycin
• Ritonavir
• Cobicistat-containing medicines

Beta-Blockers

These medicines may reduce the bronchodilator effect of vilanterol:

• Atenolol
• Metoprolol
• Propranolol
• Carvedilol

Other Long-Acting Bronchodilators

Using additional LABA-containing medicines may increase the risk of excessive cardiovascular effects:

• Salmeterol
• Formoterol
• Indacaterol
• Olodaterol

Anticholinergic Medicines

Concurrent use may increase anticholinergic effects:

• Tiotropium
• Ipratropium
• Oxybutynin
• Tolterodine
• Solifenacin

Diuretics (Water Tablets)

May increase the risk of low potassium levels:

• Furosemide
• Torsemide
• Bumetanide
• Hydrochlorothiazide

Medicines That Affect Heart Rhythm

Use with caution:

• Amiodarone
• Quinidine
• Sotalol
• Procainamide

Certain Antidepressants

May enhance cardiovascular effects:

• Amitriptyline
• Imipramine
• Nortriptyline
• Phenelzine
• Tranylcypromine

Corticosteroid Medicines

Additional corticosteroids may increase overall steroid exposure:

• Prednisolone
• Dexamethasone
• Methylprednisolone

Xanthine Derivatives

May increase the risk of low potassium levels:

• Theophylline
• Aminophylline

More Information

FAQs About BESVIL G 100 OCTACAPS

References

1. Chintan Patel , Vaishal Sheth , Ravi Koppula , Avadhesh Kumar . Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients. Pubmed. NIH. [Accessed on 22nd June 2026] [Revised in October 2025] 

2. BREO ELLIPTA. GlaxoSmithKline. US Food and Drug Administration. [Accessed on 22nd June 2026] [Revised in January 2019]